Sort   by:  
 Page size 
UnknownFour-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.

Importance

Anti-vascular endothelial growth factor (VEGF) injections in eyes with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) reduce development of vision-threatening complications from diabetes over at least 2 years, but whether this ...
S-EPMC10408259 | biostudies-literature
UnknownAflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.

Background

In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is unclear.

Methods

At 54 clinical...
S-EPMC9714135 | biostudies-literature
UnknownEvaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.

Background

The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown.

Methods

Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-con...
S-EPMC9634866 | biostudies-literature
UnknownThe power of genetic diversity in genome-wide association studies of lipids.
Increased blood lipid levels are heritable risk factors of cardiovascular disease with varied prevalence worldwide owing to different dietary patterns and medication use1. Despite advances in prevention and treatment, in particular through reducing low-density lipoprotein cholesterol leve...
S-EPMC8730582 | biostudies-literature
UnknownDrosophila muller f elements maintain a distinct set of genomic properties over 40 million years of evolution.
The Muller F element (4.2 Mb, ~80 protein-coding genes) is an unusual autosome of Drosophila melanogaster; it is mostly heterochromatic with a low recombination rate. To investigate how these properties impact the evolution of repeats and genes, we manually improved the sequence and annotated the ge...
S-EPMC4426361 | biostudies-literature
UnknownGlobal Burden of Cardiovascular Diseases and Risks, 1990-2022.
Not available
S-EPMC7615984 | biostudies-literature
UnknownForecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021.

Background

Smoking is the leading behavioural risk factor for mortality globally, accounting for more than 175 million deaths and nearly 4·30 billion years of life lost (YLLs) from 1990 to 2021. The pace of decline in smoking prevalence has slowed in recent years for many countries, and alth...
S-EPMC11447278 | biostudies-literature
UnknownBurden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840 | biostudies-literature
UnknownGlobal age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535839 | biostudies-literature
UnknownGlobal burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535838 | biostudies-literature
Sort   by:  
 Page size